fashion -WSS

fashion

author：comprehensive 2025-10-01 21:39:53 - browse：191

A follow-up study of a first-of-its-kind cancer treatment may reflect systemic biases, the Food and Drug Administration said ahead of an advisory committee meeting Thursday to determine whether the drug should remain on the market.

The treatment, Lumakras, is designed to treat lung cancer caused by a specific genetic mutation to a protein called KRAS. It’s one of the most common genetic mutations in cancer, but repeated clinical trial failures had led researchers to deem it “undruggable” until a glimmer of hope came about a decade ago.

Lumakras received an accelerated, or conditional, approval in May 2021, making it the first KRAS drug on the market. Now, the drug’s manufacturer, Amgen, needs to prove it works.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Will biotech layoffs continue through 2023?

leisure time

focus

WSS

‘We were in the air.’ Mississippi family recounts surviving tornado that tore mobile home apart

Flint parents haunted by uncertainty, fears of lead poisoning

A controversial new treatment promises to make little people taller

H.R. 3 is the wrong path to lower drug costs

VC firm RA Capital starts a new synthetic biology incubator

Ending health disparities requires full federal government, panel says

Wikipedia

fashion

hotspot

Dobbs anniversary: the lost opportunity of abortion as health care

'Hero' Louisville officer shot in head at mass shooting discharged over 3 months later

Psychedelics group wrestles with new pharma identity

Study links childhood stress with decline in older age

Medical records are filled with copy

Ford recalls 870K F

Walensky prepares to leave CDC — and Congress — behind

When waiting feels immoral: Empathy in the emergency department

Moonlake's readout produced a cash windfall. Risks remain

Moscow blames Kyiv for missile attacks in southern Russia as Kremlin forces pound Ukrainian village

knowledge

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

The cancer stories no one wants to hear

How I helped Pfizer think through the ethics of Viagra

Behind warning on Apellis’s eye drug lies a conflict of interest

'The boss' wants server deleted: New allegations emerge in Trump indictment

Biden to sign 'historic' executive order on how US military handles sexual assault cases

leisure time

focus

knowledge

hotspot